Isofol AGENT is a biotechnology company based in Göteborg, Sweden. The company specializes in the development of innovative therapies for cancer treatment, focusing on improving the efficacy and safety of existing treatment options. Isofol is known for its proprietary drug candidate, which aims to enhance the therapeutic outcomes for patients undergoing chemotherapy.
The company is engaged in various stages of clinical development, working to advance its products through rigorous testing and regulatory processes. Isofol AGENT collaborates with academic institutions and other organizations to further research and development efforts in the field of oncology. Its commitment to scientific innovation is reflected in its ongoing projects aimed at addressing unmet medical needs in cancer care.